ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT

被引:151
作者
Ceconi, Claudio
Fox, Kim M.
Remme, William J.
Simoons, Marteen L.
Bertrand, Michael
Parrinello, Giovanni
Kluft, Cornelius
Blann, Andrew
Cokkinos, Dennis
Ferrari, Roberto
机构
[1] Univ Ferrara, I-44100 Ferrara, Italy
[2] IRCCS, Cardiovasc Pathophysiol Res Ctr, Salvatore Maugeri Fdn, Brescia, Italy
[3] Royal Brompton Hosp, London SW3 6LY, England
[4] Cardiovasc Res Fdn, Rhoon, Netherlands
[5] Erasmus Univ, Med Ctr, Ctr Thorax, Rotterdam, Netherlands
[6] Hop Cardiol, F-59037 Lille, France
[7] Univ Brescia, Med Stat Unit, Brescia, Italy
[8] TNO, PG, Gaubius Lab, Dept Vasc & Connect Tissue Res, Leiden, Netherlands
[9] Univ Birmingham, Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham, W Midlands, England
[10] Onassis Cardiac Surg Ctr, Athens, Greece
关键词
inhibition; perindopril; endothelial function; von Willebrand factor;
D O I
10.1016/j.cardiores.2006.10.021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease [EUROPA] demonstrates reduction in cardiovascular mortality and myocardial infarction for a possible vascular and antiatherosclerotic effect of angiotensin-converting enzyme (ACE) inhibition with perindopril. Our objective was to study the effect of perindopril on endothelial function and to verify its link to risk and occurrence of cardiovascular events. Methods: Blood from 1200 EUROPA patients was withdrawn at baseline and after 1 year of treatment with either perindopril or placebo to measure von Willebrand factor and from 45 healthy subjects and 97 EUROPA patients to study endothelial function at the cellular level by cultivating in vitro human umbilical vein endothelial cells. In this setting, we determined protein expression/activity of endothelial nitric oxide synthase and the rate of apoptosis. Plasma levels of angiotensin II, bradykinin, tumor necrosis factor alpha, and nitrite/nitrate were also measured. Results: The occurrence of cardiovascular events was related to von Willebrand factor at baseline (P=0.013) that also significantly decreased after 1 year's treatment (P < 0.001). Perindopril upregulated 19% and 27% protein expression/activity of endothelial nitric oxide synthase (P < 0.05) as well as reduced the rate of apoptosis by 31% (P < 0.05). There was also a significant reduction in levels of angiotensin II, increase in bradykinin, reduction in tumor necrosis factor alpha, and increase in nitrite/nitrate (P < 0.05 for all). Conclusions: Abnormal endothelial function occurs in patients with coronary artery disease, and this can be counteracted by angiotensin-converting enzyme inhibition with perindopril. These effects could contribute, at least in part, to explaining the results of the main EUROPA Study. (c) 2006 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:237 / 246
页数:10
相关论文
共 34 条
  • [1] Serum from patients with severe heart failure downregulates eNOS and is proapoptotic -: Role of tumor necrosis factor-α
    Agnoletti, L
    Curello, S
    Bachetti, T
    Malacarne, F
    Gaia, G
    Comini, L
    Volterrani, M
    Bonetti, P
    Parrinello, G
    Cadei, M
    Grigolato, PG
    Ferrari, R
    [J]. CIRCULATION, 1999, 100 (19) : 1983 - 1991
  • [2] Co-expression and modulation of neuronal and endothelial nitric oxide synthase in human endothelial cells
    Bachetti, T
    Comini, L
    Curello, S
    Bastianon, D
    Palmieri, M
    Bresciani, G
    Callea, F
    Ferrari, R
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 37 (05) : 939 - 945
  • [3] Ace-inhibition with quinapril modulates the nitric oxide pathway in normotensive rats
    Bachetti, T
    Comini, L
    Pasini, E
    Cargnoni, A
    Curello, S
    Ferrari, R
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2001, 33 (03) : 395 - 403
  • [4] BALL SG, 1993, LANCET, V342, P821
  • [5] PERindopril -: Function of the endothelium in coronary artery disease trial:: The PERFECT study -: Sub study of EUROPA:: Rationale and design
    Bots, ML
    Remme, WJ
    Lüscher, TF
    Grobbee, DE
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2002, 16 (03) : 227 - 236
  • [6] Braunwald E, 2004, NEW ENGL J MED, V351, P2058
  • [7] BRADYKININ PEPTIDES IN KIDNEY, BLOOD, AND OTHER TISSUES OF THE RAT
    CAMPBELL, DJ
    KLADIS, A
    DUNCAN, AM
    [J]. HYPERTENSION, 1993, 21 (02) : 155 - 165
  • [8] Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril
    Cargnoni, A
    Comini, L
    Bernocchi, P
    Bachetti, T
    Ceconi, C
    Curello, S
    Ferrari, R
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2001, 133 (01) : 145 - 153
  • [9] Endothelial cell apoptosis: Biochemical characteristics and potential implications for atherosclerosis
    Choy, JC
    Granville, DJ
    Hunt, DWC
    McManus, BM
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2001, 33 (09) : 1673 - 1690
  • [10] The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy
    Daly, CA
    Fox, KM
    Remme, WJ
    Bertrand, ME
    Ferrari, R
    Simoons, ML
    [J]. EUROPEAN HEART JOURNAL, 2005, 26 (14) : 1369 - 1378